X0306 4 2021-02-10 0 0001811063 Nuvation Bio Inc. NUVB 0001454385 NODELMAN OLEG 357 TEHAMA STREET, #3 SAN FRANCISCO CA 94103 1 0 1 0 0001816134 EcoR1 Panacea Holdings, LLC 357 TEHAMA STREET, #3 SAN FRANCISCO CA 94103 0 0 1 0 0001567938 EcoR1 Capital Fund, L.P. 357 TEHAMA STREET, #3 SAN FRANCISCO CA 94103 0 0 1 0 0001598292 EcoR1 Capital Fund Qualified, L.P. 357 TEHAMA STREET, #3 SAN FRANCICSO CA 94103 0 0 1 0 0001778011 EcoR1 Venture Opportunity Fund, LP 357 TEHAMA STREET, #3 SAN FRANCISCO CA 94103 0 0 1 0 0001587114 EcoR1 Capital, LLC 357 TEHAMA STREET, #3 SAN FRANCISCO CA 94103 0 0 1 0 0001816370 Biotech Opportunity GP, LLC 357 TEHAMA STREET, #3 SAN FRANCISCO CA 94103 0 0 1 0 Class A Common Stock 2021-02-10 4 C 0 2775000 0.00 A 3165000 I By Limited Liability Company Class A Common Stock 2021-02-10 4 A 0 2106000 A 2106000 I By Limited Partnership Class A Common Stock 2021-02-10 4 A 0 394000 A 394000 I By Limited Partnership Class A Common Stock 2021-02-10 4 A 0 2112735 10.00 A 4218735 I By Limited Partnership Class A Common Stock 2021-02-10 4 A 0 387265 10.00 A 781265 I By Limited Partnership Class A Common Stock 2021-02-10 4 A 0 2365511 0.00 A 6584246 I By Limited Partnership Class A Common Stock 2021-02-10 4 A 0 515879 0.00 A 1297144 I By Limited Partnership Class A Common Stock 2021-02-10 4 A 0 2200627 0.00 A 2200627 I By Limited Partnership Class B Common Stock 2021-02-10 4 C 0 2775000 0.00 D Class A Common Stock 2775000 0 I By Limited Liability Company Warrant (Right to Buy) 11.50 2021-02-10 4 A 0 130000 0.00 A 2021-07-06 Class A Common Stock 130000 130000 I By Limited Liability Company Warrant (Right to Buy) 11.50 2021-02-10 4 A 0 702000 0.00 A 2021-07-06 Class A Common Stock 702000 702000 I By Limited Partnership Warrant (Right to Buy) 11.50 2021-02-10 4 A 0 131333 0.00 A 2021-07-06 Class A Common Stock 131333 131333 I By Limited Partnership Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination (as defined below), an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). Oleg Nodelman is the manager of EcoR1 Venture Opportunity Fund, LP, which is the owner of record of these securities. 5:00 p.m., New York City time, on February 10, 2026. Warrants included in units purchased in a private placement by EcoR1 Panacea Holdings, LLC for $10.00 per unit in connection with Panacea's initial public offering. Each unit consisted of one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. Upon the closing of the Business Combination, the warrants may be deemed to be derivative securities for purposes of Section 16. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act. Oleg Nodelman may be deemed to be a beneficial owner of shares held by each of the other Reporting Persons but disclaims beneficial ownership of any such shares except to the extent of his pecuniary interest therein. Oleg Nodelman, the manager of each of the General Partners, serves on the board of directors of Nuvation Bio Inc. For the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons (other than Mr. Nodelman) may be deemed a director by deputization with respect to the issuer on the basis of Mr. Nodelman's service on the issuer's board of directors. /s/ Ron A. Metzger, as an authorized signatory for each Reporting Person. 2021-02-12